In 2015, global funding for HIV prevention R&D declined slightly, from US $1.25 billion in 2014 to US $1.20 billion in 2015. This continues a decade of roughly flat funding. The US public sector remained the largest global contributor at US $850 million, and together with the Bill & Melinda Gates Foundation, the largest philanthropic funder, constituted 81 percent of all funding.
Global HIV Prevention R&D Investments by Technology, 2000-2015
Slow and Steady Won’t Win the Prevention Race
Progress in voluntary medical male circumcision has made significant gains but still fell short of targets—or why VMMC isn’t a global priority and how to make it one. Excerpted from AVAC Report 2016: Big Data, Real People.
PrEP for MSM in Africa: Meeting Summary and Next Steps
Advocates gather in South Africa for the continent’s first PrEP and MSM consultation to chart a path for PrEP access. See the report summary with links to presentations and country plans.
Programs but Not Yet Platforms: The peril and promise of women’s biomedical HIV prevention in 2016
The benefits of PrEP is winning over support from international bodies and an increasing number of national governments. PrEP introduction is advancing on several fronts, but all this momentum has yet to impact some of the people who need it most, in particular, adolescent girls and young women with high risk of acquiring HIV. Check out our up-close look at the issue from AVAC 2016’s Big Data, Real People.
MPT Product Development: Many possibilities for MPT development
This table shows the indication (prevention effect the product is designed to have—e.g., pregnancy or one or more STIs) the way it will be delivered (e.g., through vaginal gel, pill or injection), how it might work to provide preventive effect (for example, as a physical barrier to prevent fluid exchange or as a hormonal contraceptive) and what kind of dosage could be possible (e.g., daily pill or application, sustained through the blood or around sex).
Excerpted from the MPTs factsheet.
New Analysis on Hormonal Contraception and HIV: WHO and others must act
An update excerpted from AVAC Report 2016: Big Data, Real People.
Px Wire July-September 2016, Vol. 9, No. 3
The International AIDS Conference in Durban was a reminder of how important the meeting can be in framing global issues and priorities. This issue of Px Wire offers a look at how the Durban wrap-up catapults us into the future.
The centerspread graphic features a scorecard for the conference (did it deliver?) and a novel look at how to use today’s tools to break the cycle of heterosexual transmission that was so clearly defined in a major Durban presentation.
Durban 2016 Scorecard—How did it deliver?
Excerpted from Px Wire, this is a scorecard for the 2016 International AIDS Conference. Did it deliver?
Breaking the Cycle of Heterosexual Transmission
Excerpted from Px Wire, this is a novel look at how to use today’s tools to break the cycle of heterosexual transmission that was so clearly defined in a major AIDS 2016 presentation.
ARV-Based Prevention Pipeline
The pipeline of ARV-based prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable ARVs. Not pictured are a range of multipurpose technologies in development that aim to reduce women’s risk of HIV and STIs, and provide effective contraception.